EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, OPHLF: Ono Pharmaceutical Co. Ltd

24 Nov 2025
LAST:

13.28

CHANGE:
 0.25		OPEN:
13.28		HIGH:
13.28		ASK:
0.00		VOLUME:
1.0K
CHG(%):
1.92		PREV:
13.03		LOW:
13.28		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Nov 2513.2813.2813.2813.281.0K
20 Nov 2513.0313.0313.0313.03400

PROFILE

Name:Ono Pharmaceutical Co. Ltd
About:Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Sector:Healthcare
Address:8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
Website:https://www.ono-pharma.com
CIK:0000940821
FIGI:BBG000D1WTB1

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:14.38 
Forward P/E:13.87 
Price to Sales:0.01 
Price to Book:0.93 
DivYield:0.05 
Div/Share:80.00 
Revenue:496.732B 
EBITDA:86.189B 
Shares:469.77M 
Market Cap:6.239B 

TECHNICAL INDICATORS

MA5:12.327.8%
MA10:11.8312.3%
MA20:11.3217.3%
MA50:10.9021.8%
STO9:100.00 
STO14:100.00 
RSI14:61.58 
MTM14:2.18
ROC14:0.20 
ATR:0.86 
Week High:13.280.0%
Week Low:13.031.9%
Month High:13.280.0%
Month Low:11.08
Volatility:101.06